Active Ingredient: DARIDOREXANT
Daridorexant (a dual orexin receptor antagonist - DORA) does not affect cardiac repolarization. In a thorough QT study of 36 healthy subjects, single therapeutic (50 mg) and supratherapeutic (200 mg) doses were evaluated. The placebo-adjusted mean change in QTcF was 1.40 ms for the 50 mg dose and 1.84 ms for the 200 mg dose (Cmax up to 1809 ng/mL). The upper 90% confidence intervals remained well below the 10 ms regulatory threshold.
https://doi.org/10.1007/s40261-021-01062-1